Free Trial

Affirm Holdings, Inc. (NASDAQ:AFRM) Given Consensus Rating of "Moderate Buy" by Brokerages

Affirm logo with Business Services background

Shares of Affirm Holdings, Inc. (NASDAQ:AFRM - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty-three research firms that are currently covering the firm, MarketBeat reports. Eight equities research analysts have rated the stock with a hold recommendation, fourteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $67.00.

A number of research firms have recently commented on AFRM. The Goldman Sachs Group dropped their price objective on shares of Affirm from $90.00 to $56.00 and set a "buy" rating for the company in a research note on Tuesday, March 18th. UBS Group increased their price target on shares of Affirm from $46.00 to $62.00 and gave the stock a "neutral" rating in a research note on Friday, February 7th. Wells Fargo & Company lowered their price objective on shares of Affirm from $85.00 to $67.00 and set an "overweight" rating for the company in a research note on Wednesday, April 9th. Seaport Res Ptn upgraded Affirm to a "hold" rating in a report on Monday, March 24th. Finally, JMP Securities upped their price target on Affirm from $78.00 to $85.00 and gave the stock a "market outperform" rating in a research note on Friday, February 7th.

Read Our Latest Stock Report on Affirm

Affirm Price Performance

Shares of NASDAQ:AFRM opened at $51.54 on Thursday. The business's fifty day moving average price is $46.78 and its two-hundred day moving average price is $56.51. The company has a debt-to-equity ratio of 2.68, a quick ratio of 11.26 and a current ratio of 11.26. The stock has a market cap of $16.39 billion, a PE ratio of -79.29 and a beta of 3.66. Affirm has a one year low of $22.25 and a one year high of $82.53.

Affirm (NASDAQ:AFRM - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.44. Affirm had a negative return on equity of 7.25% and a negative net margin of 7.10%. On average, analysts forecast that Affirm will post -0.18 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Noel Bertram Watson sold 2,500 shares of Affirm stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $45.78, for a total value of $114,450.00. Following the completion of the transaction, the director now owns 38,997 shares in the company, valued at approximately $1,785,282.66. This trade represents a 6.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Keith Rabois sold 16,088 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $63.97, for a total value of $1,029,149.36. Following the sale, the director now directly owns 61,520 shares in the company, valued at approximately $3,935,434.40. This represents a 20.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 55,765 shares of company stock valued at $3,094,694 in the last ninety days. Corporate insiders own 12.41% of the company's stock.

Institutional Trading of Affirm

A number of institutional investors and hedge funds have recently modified their holdings of AFRM. Allworth Financial LP grew its position in shares of Affirm by 63.7% during the 1st quarter. Allworth Financial LP now owns 563 shares of the company's stock valued at $27,000 after buying an additional 219 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new stake in Affirm in the fourth quarter worth $28,000. Geneos Wealth Management Inc. lifted its stake in Affirm by 356.5% in the fourth quarter. Geneos Wealth Management Inc. now owns 525 shares of the company's stock valued at $32,000 after buying an additional 410 shares during the last quarter. R Squared Ltd acquired a new position in shares of Affirm during the fourth quarter valued at $33,000. Finally, Coppell Advisory Solutions LLC bought a new position in shares of Affirm during the fourth quarter worth about $40,000. 69.29% of the stock is owned by institutional investors and hedge funds.

About Affirm

(Get Free Report

Affirm Holdings, Inc operates a platform for digital and mobile-first commerce in the United States, Canada, and internationally. The company's platform includes point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. Its commerce platform, agreements with originating banks, and capital markets partners enables consumers to pay for a purchase over time with terms ranging up to 60 months.

Recommended Stories

Analyst Recommendations for Affirm (NASDAQ:AFRM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Affirm Right Now?

Before you consider Affirm, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Affirm wasn't on the list.

While Affirm currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Blowout Earnings Winners That Could Soar Even Higher
5 Stocks You’ve Never Heard Of That I’m Buying Nonstop in 2025
3 Sectors With Massive Momentum You Can’t Afford to Miss

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines